American Oriental Bioengineering, Inc. (NYSE: AOB a pharmaceutical company announced that it plans to release third quarter 2009 financial results on Monday, November 16, 2009, after the market closes.
On CAPS, 97% of the 3,140 members rated this stock to outperform the S&P 500 going forward and this stock is not rated on CAPS for nothing " Companies in China will continue to grow, even the poorly run ones, simply due to the massive socio-economic shift of the growing Chinese middle class. As people acquire wealth, the number one place they put it is in securing health (their own, and that of their children). The Chinese are no different, and AOB has huge advantage selling into that market -- it knows it, and it sells niche products that have a cultural moat that's hard to beat. This stock is easily a 10 bagger over the next decade"
<font> http://www.fool.com/investing/general/2009/11/13/5-star-stock... </font>
"According to Jubak, the Chinese government is making a substantial push to expand the country's healthcare sector. American Oriental Biology ought to benefit from this initiative. The price is right at 1.04 times book value and 6 times estimated earnings in 2010 (i.e. $0.77 per share). The balance sheet is good and historical sales growth is phenomenal. Stockscouter rating is 7."
<font> http://msncaps.fool.com/Ticker/AOB.aspx </font>
recommendation is Moderate Buy .
Pro The price-to-earnings multiple is lower than average for all stocks in the StockScouter universe. Positive The StockScouter measure of relative price change and consistency is high. Positive Con The most recent quarterly earnings report was slightly lower than analysts’ consensus forecast. Neutral/Negative Earnings growth in the past year has decelerated moderately compared to earnings growth in the past three years. 
$4.09 (11/15/09)
